Literature Search
Results
Study/year of publication | Patients (n) | F/M | Age range (years) | AC/SCC/other | Stage diseasea
| Treatment | SUV predictor of survival (univariate) | SUV independent predictor survival (multivariate) | Other independent predictive factors |
---|---|---|---|---|---|---|---|---|---|
Fukunaga/199833
| 48 | 5/43 | 44–76 | ND | II–IV | Resection | Yes (OS) | – | – |
Kato/200235
| 32 | 3/29 | 42–76 | –/32/– | I–IV | Resection | Yes (OS) | – | – |
Kato/200336
| 44 | – | 42–76 | –/44/– | ND | Resection | Yes (OS) | – | – |
Choi/200431
| 69 | 5/64 | – | –/69/– | I–IV | Resection ± adjuvant CRT | Yes (OS) | No | cTNM, pTNM, PET-tumor length, PET + lnn |
Hong/200534
| 47 | 4/43 | 36–78 | 41/6/– | II–III (cTNM) | Neoadjuvant CRT + resection | No | No | Number of PET abnormalities |
Stahl/200540
| 40 | – | – | 40/–/– | II–IV (cTNM) | Resection ± neoadjuvant CT | No | – | – |
van Westreenen/200543
| 40 | 16/24 | 48–79 | 28/12/– | I–IV (cTNM) | Resection/palliation | Yes (OS) | No | Resection |
Cerfolio/200630
| 89 | 36/53 | 29–81 | 47/32/10 | I–IV | Resection ± neoadjuvant CRT | Yes (OS) | Yes (OS) | TNM |
Choi/200632
| 51 | 4/47 | 41–77 | –/51/– | I–IV | Resection ± adjuvant CRT | Yes (OS) | No | pTNM, intratumoral MVD, PET + lnn, VEGF expression |
Rizk/200639
| 50 | 6/44 | – | 50/–/– | I–IV | Resection | Yes (OS) | – | – |
Westerterp/200844
| 26 | 3/23 | 48–79 | 26/–/– | I–IV | Resection ± Cox-2 inhibitor | Yes (DFS) | – | – |
Omloo/200856
| 125 | 21/104 | 37–82 | 106/19/– | I–III | Resection | Yes (DFS) | No | EUS T-stage, tumor location, EUS N-stage, cTNM |
Cheze-Le Rest/200853
| 47 | 5/42 | 41–89 | 11/36/– | I–IV | Resection ± neo/adjuvant CT ± RT | Yes (OS) | Yes (OS) | Treatment, number of PET abnormalities, PET + LNN, number of PET + LNN |
Chatterton/200852
| 129 | 25/104 | 36–87 | 99/25/5 | I–IV | Resection ± CT ± RT/palliation | No (DFS) | ND | Additional PET lesions |
Makino/200855
| 38 | 7/31 | 50–76 | –/38/– | I–IV | Neoadjuvant CT + resection | Yes (DFS) | No | PET + LNN, SUV decrease, pT, pN |
Study/year of publication | Patients (n) | F/M | Age range (years) | AC/SCC/other | Stage of diseasea
| Treatment | SUV predictor of survival (univariate) | SUV independent predictor survival (multivariate) | Other independent predictive factors |
---|---|---|---|---|---|---|---|---|---|
Swisher/200441
| 83 | 9/74 | 34–79 | 73/10/– | 0–IV | Neoadjuvant CRT ± induction CT + resection | Yes (OS) | No | – |
Swisher/200442
| 103 | 12/91 | 34–79 | 90/13/– | II–IVa (cTNM) | Neoadjuvant CRT ± induction CT + resection | Yes (OS) | Yes (OS) | Esophageal wall thickness on CT (post-CRT) |
Konski/200737
| 81 | 14/67 | – | 66/15/– | II–IVa (cTNM) | Definitive CRT/neoadjuvant CRT + resection | Yes, definitive CRT patients (OS) | No | No |
Mamede/200738
| 25 | 3/22 | ND | 22/3/– | 0–IVa | Neoadjuvant CRT + resection | Yes (DFS) | – | – |
Higuchi/200854
| 50 | 9/41 | 44–77 | –/50/– | III–IV | Neoadjuvant CT ± RT + resection | Yes (DFS) | ND | – |
Study/Year of publication | Patients (n) | F/M | Age range (years) | AC/SCC/other | Stage of diseasea
| Treatment | Prevalence respondersb
| SUV decrease predictor of response | SUV decrease predictor of survival | Absolute SUV available |
---|---|---|---|---|---|---|---|---|---|---|
Group 2A | ||||||||||
Weber/200149
| 40 | 3/37 | 25–69 | 40/–/– | 0–IV | Neoadjuvant CT + resection | 31% (11/35) | Yes | Yes (OS + DFS) | Yes |
Ott/200647
| 65 | 7/58 | 50–66 | 65/–/– | 0–IV | Neoadjuvant CT + resection | 18% (10/56) | Yes | Yes (OS) | Yes |
Lordick/200714
| 119 | 8/111 | ND | 119/–/– | 0–IV | Neoadjuvant CT + resection | 69% (37/56)c
| Yes | Yes (OS + DFS) | Yes |
Wieder/200751
| 24 | 4/20 | 33–71 | 24/–/– | 0–IV | Neoadjuvant CT + resection | 33% (8/24) | Yes | Yes (OS) | Yes |
Wieder/200450
| 38 | 11/27 | 46–73 | –/38/– | 0–IV | Neoadjuvant CRT + resection | 58% (19/33) | Yes | Yes (OS) | Yes |
Westerterp/200616
| 26 | 2/24 | 29–73 | 20/6/– | 0–IVa | Neoadjuvant ThCRT + resection | 42% (10/24) | Yes | Nod
| Yes |
Group 2B | ||||||||||
Port/200748
| 62 | 10/52 | 36–76 | 51/11/– | 0–IV | Neoadjuvant CT + resection | 16% (10/62) | Yes | Yes (DFS) | No |
Makino/200855
| 38 | 7/31 | 50–76 | –/38/– | I–IV | Neoadjuvant CT + resection | 59% (20/34) | – | Yes (DFS) | Yes |
Downey/200345
| 39 | 5/34 | 36–76 | 26/13/– | 0–III | Neoadjuvant CT ± RT + resection | 24% (4/17) | – | No | No |
Levine/200646
| 64 | 11/53 | 42–84 | 52/12/– | I–IV | Neoadjuvant CRT + resection | 42% (20/48) | No | – | Yes |
Mamede/200738
| 25 | 3/22 | ND | 22/3/– | 0–IVa | Neoadjuvant CRT + resection | 32% (8/25) | Yes | Yes (DFS) | Yes |
Roedl/200958
| 49 | 10/39 | ND | –/49/– | II–III | Neoadjuvant CRT + resection | 45% (22/49) | – | No | No |
Roedl/200857
| 51 | 5/46 | ND | 51/–/– | I–IVa | Neoadjuvant CRT + resection | 41% (21/51) | Yes | Yes (DFS) | No |
Schmidt/200959
| 55 | 12/43 | 34–74 | 31/24/– | III–IVa | Neoadjuvant CRT + resection | 38% (21/55) | No | No | Yes |
Swisher/200441
| 83 | 9/74 | 34–79 | 73/10/– | 0–IV | Neoadjuvant CRT ± induction CT + resection | 54% (43/79) | – | – | Yes |
Swisher/200442
| 103 | 12/91 | 34–79 | 90/13/– | II–IVa (cTNM) | Neoadjuvant CRT ± induction CT + resection | 56% (58/103) | No | No | Yes |
Study/Year of publication | Single/Multicenter | Scanner | Reconstruction methods | ROI methods | Injected dose FDG (MBq) | Time between injection and scan | Quantification method | SUV max or SUV mean iso 50%/70% | Corrected for | Plasma glucose measurements | Absolute values (SUV, range) | Cutoff values |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fukunaga/199833
| Single | HEAD-TOME III (Shimazu Works, Kyoto, Japan) | Ramp-filter + Butterworth filter, 10.5 mm FWHM | Site of maximum accumulation (9 pixels: 9 × 9 mm2) | 148 | 60 min | SUV | SUV max | BW | Noa
| 1.51–16.13 | 7.0 |
Single | SET 2400W (Shimadzu Corporation, Kyoto, Japan) | OSEM, 4.2 mm FWHM | Manually drawn 1 cm in dimension at site of tumor | 275–370 | 40 min | SUV | SUV max | BW | No | 1.43–9.0 | 3.0 | |
Single | Advance PET scanner (General Electric Medical Systems, Milwaukee, WI) | FBP, Hanning-filter, 8.0 mm | ND | 370 | 45 min | SUV | SUV max | BW | No | – | 6.3, 13.7 | |
Hong/200534
| Single | ND | ND | ND | ND | ND | SUVb
| Peak SUV, SUV primary and total SUV | ND | No | – | 4.0 |
Stahl/200540
| Single | ECAT EXACT (Siemens, Knoxville, TN) | OSEM 8 iterations/4 subsets, 3D Gaussian filter 4 mm FWHM | Manually placed circular ROI of 1.5 cm on tumor site maximal FDG accumulation | 400 | 90 min | SUV | SUV max | BW | Yes | – | 10.5 |
van Westreenen/200543
| Single | ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN) | OSEM, filter ND | 3D ROI selected semi-automatically | 130–690 | 90 min | SUV | SUV max and SUV mean iso 70% | BW | No | 1.8–19.2 | 6.7 |
Cerfolio/200630
| Single | ECAT EXACT (CTI, Knoxville, TN)/integrated PET-CT (Discovery LS, General Electric, Milwaukee, WI) | ND | Manually drawn ROI around tumor | 555 | 60 min | SUV | SUV max | BW | No | – | 6.6 |
Rizk/200639
| Single | Advance PET scanner (General Electric Medical Systems, Milwaukee, WI)/CTI Biograph (CTI, Knoxville, TN) | ND | ROI analysis tools delivered with scanner | 370–555 | ND | SUV | SUV max | BW | No | 1.9–19.1 | 4.5 |
Konski/200737
| Single | Integrated PET-CT (Discovery LS, General Electric, Waukesha, WI) | 2D, OSEM 2 iterations/28 subsets, Gaussian filter 10 mm FWHM | ND | 370–740 | 90–120 min | SUVb
| SUV max | BW | Yes | – | – |
Westerterp/200844
| Single | ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN) | 2D, OSEM 2 iterations/16 subsets, Gaussian filter 5 mm FWHM | VOI generated by 3D region-growing algorithm with in-home developed software | 350–597 | 90 min | SUV | SUV max and SUV mean iso 50% | BSA, glucose | Yes | 0.03–0.63 | 0.26 |
Omloo/200856
| Multi | ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN) | 2D, OSEM 2 iterations/16 subsets, Gaussian filter 5 mm FWHM | VOI generated by 3D region-growing algorithm with in-home developed software | 130–810 | 90 min | SUV | SUV max and SUV mean iso 50% | BSA, glucose | Yes | 0.13–0.45 (IQR) | 0.27 |
Cheze-Le Rest/200853
| Single | Allegro-dedicated PET scanner (Philips Medical System, Cleveland, OH) | 3D RAMLA reconstruction protocol | ROI analysis highest uptake | 5 MBq/kg | 60 min | SUV | SUV max | BW | Yes | 9.3 ± 3.9 (mean, 1SD) | 9 |
Chatterton/200852
| Single | ND | ND | ND | 120–400 | 45 min | SUV | SUV max | BW | No | – | 8.2 |
Higuchi/200854
| Single | PET scanner HEADTOME/set 2400W (Shimadzu Co, Kyoto, Japan) | ND | ROI selected semiautomatically | 370 | 60 min | SUV | SUV max | BW | Yes | – | 2.5 |
Study/Year of publication | Single/Multicenter | Scanner | Reconstruction methods | ROI methods | Injected dose FDG (MBq) | Time between injection and scan | Quantification method | SUV max or SUV mean iso 50%/70% | Corrected for | Plasma glucose measurements | Absolute values (SUV, range) | Cutoff value responding vs nonresponding |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Weber/200149
a
| Single | ND | FBP, Hanning filter 0.4, 6–8 mm FWHM | Manually placed circular ROI of 1.5 cm on tumor site maximal FDG accumulation | 250–370 | 40 min | SUV | SUV max | BSA | Yes | 5.0–50.3 | −35% |
Wieder/200450
| Single | ECAT EXACT (Siemens/CTI, Knoxville, TN) | OSEM 8 iterations/4 subsets, 3D Gaussian filter 4 mm FWHM | Manually placed circular ROI of 1.5 cm on tumor site maximal FDG accumulation | 300–400 | 60 min | SUV | SUV max | BW | Yes | 0.9–15.4 | −30% |
Westerterp/200616
| Single | ECAT EXACT HR + (Siemens/CTI, Knoxville, TN) | 2D, OSEM 2 iterations/16 subsets, Gaussian filter 5 mm FWHM | VOI generated by 3D region growing algorithm with in-home developed software | 250–370 | 90 min | SUV | SUV mean iso 50% | BSA, glucose | Yes | 0.1–0.5 | −31% |
Ott/200647
a
| Single | ND | OSEM 8 iterations/4 subsets, 3D Gaussian filter 4 mm FWHM | Manually placed circular ROI of 1.5 cm on tumor site maximal FDG accumulation | 250–370 | 40 min | SUV | SUV max | BW | Yes | – | −35% |
Wieder/200751
| Single | ECAT EXACT (Siemens/CTI, Knoxville, TN) | OSEM 8 iterations/4 subsets, 3D Gaussian filter 4 mm FWHM | Manually placed circular ROI of 1.5 cm on tumor site maximal FDG accumulation | 300–400 | 40 min | SUV | SUV max | BW | Yes | – | −33% |
Lordick/200714
a
| Single | ECAT EXACT full ring (Siemens/CTI, Knoxville, TN) | 3D, OSEM 8 iterations/4 subsets, FBP Hanning filter 0.4, 6–8 mm FWHM | Manually placed circular ROI of 1.5 cm on tumor site maximal FDG accumulation | 300–400 | 40 min | SUV | SUV max | BSA | Yes | – | −35% |
Study/year of publication | Single/multicenter | Scanner | Reconstruction methods | ROI methods | Time between injection and scan | Injected dose FDG (MBq) | Quantification method | SUV max or SUV mean iso 50%/70% | Corrected for | Plasma glucose measurements | Absolute values (SUV, range) | Cutoff value responding vs nonresponding |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Downey/200345
| Single | Advance PET scanner (General Electric Medical Systems, Milwaukee, WI) | FBP, ND | ROI analysis tools delivered with scanner | ND | >370 | SUV | SUV max | ND | No | – | −60% |
Single | ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN) | OSEM 2 iterations/8 subsets, Gaussian filter 4.5 mm FWHM | Manually placed ROI on tumor site with FDG accumulation | 45/60 min | 555–740 | SUV | SUV max | BW | No | – | 4.0 (SUV) | |
Levine/200646
| Single | Advance PET scanner (General Electric Medical Systems, Milwaukee, WI) | ND | ROI analysis tools delivered with scanner | 60 min | 555–740 | SUV | SUV max | LBM | Yes | 0–36.6 | >−10.0 (SUV) |
Port/200748
| Single | Advance PET scanner (General Electric Medical Systems, Milwaukee, WI) | ND | ND | 45–60 min | 370–555 | SUV | SUV max | ND | No | – | −50% |
Mamede/200738
| Single | Integrated PET-CT (Discovery LS, General Electric, Milwaukee, WI) | OSEM 2 iterations/30 subsets | Manually placed circular ROI of 1.5 cm on tumor site maximal FDG accumulation | ±80 min | PET 1: 813 ± 144 PET 2: 720 ± 91 | SUV | SUV max | BW | Yes | – | −32% |
Roedl/200858
| Single | Biograph 16 integrated PET/CT scanner (Siemens, Erlangen, Germany) | ND | Delineated automatically including pixels equal/greater to SUV 2.5 | 60 min | 555 | SUV | SUV max + SUV mean | BW | No | – | 55% (diameter SUV index) |
Makino/200855
| Single | HEADTOME/SET 2400W (Shimadzu, Kyoto, Japan) | Iterative median root + reconstruction algorithm, filter 3.7 mm FWHM | ROI of 10 pixels on tumor site maximal FDG accumulation | 60 ***min | 370 | SUV | SUV max | BW | Yes | 11.12 ± 4.32 (mean ± SEM) | −70% |
Roeld/200857
| Single | Biograph 16 integrated PET/CT scanner (Siemens, Erlangen, Germany) | ND | Delineated automatically including pixels equal/greater to SUV 2.5 | 60 min | 555 | SUV | SUV max + SUV mean | BW | No | – | −63% (PET-CT volume) |
Schmidt/200859
| Single | ECAT EXACT 47 scanner (Siemens Medical Systems, Siemens CTI, Knoxville, TN) | OSEM 2/iterations, 8 subsets, Gaussian filter 6 mm FWHM | Circular 10 pixel standard region + spherical ROI in maximal FDG accumulation | 60 min | 370 | SUV | SUV max + SUV mean | BW | Yes | 1.8–19.4 | SCC, −70% AC, −22% |